

ORIGINAL

FILED
HARRISBURG

OCT 10 2000

MARY E. D'ANDREA, CLERK
Per

DEPUTY CLERK

ATTORNEYS FOR DEFENDANT
WILLIAM J. STEINOUR, M.D.

POST & SCHELL, P.C.
BY: JOHN R. KANTNER, ESQUIRE
I.D. # 75741
240 GRANDVIEW AVENUE
CAMP HILL, PA 17011
(717) 731-1970

JASON ERIC BENSON,

Plaintiff

v.

WARDEN THOMAS DURAN,
DEPUTY WARDEN BRUCE CLUCK,
DEPUTY WARDEN DEBRA HANKEY,
LT. JOHN JENNINGS, LT. WILLIAM ORTH,
SGT. RAE HIENTZELMAN,
C.O. BRITON SHELTON,
C.O. DAVID VAZQUEZ,
C.O.s JANE/JOHN DOE,
DR. WILLIAM J. STEINOUR,
ADAMS COUNTY PRISON,

Defendants

IN THE UNITED STATES DISTRICT
COURT FOR THE MIDDLE DISTRICT
OF PENNSYLVANIA

NO. 1:CV-00-1229

(JUDGE CALDWELL)

(MAGISTRATE JUDGE BLEWITT)

**MOTION OF DEFENDANT WILLIAM STEINOUR, M.D.
TO DISMISS PLAINTIFF'S AMENDED COMPLAINT**

AND NOW, comes Defendant William Steinour, M.D., by and through his attorneys, Post & Schell, P.C., and for his Motion to Dismiss the Complaint pursuant to F.R.C.P. 12(b)(6), states as follows:

1. This is an action for violation of civil rights pursuant to 42 U.S.C. §1983. Specifically, Plaintiff alleges violation of his civil rights protected by the Eighth Amendment of the U.S. Constitution, for alleged deliberate indifference to serious medical needs. A copy of the Amended Complaint is attached as Exhibit "A".

2. As alleged in the Complaint, Defendant Dr. Steinour is a physician employed at the Gettysburg Hospital, being sued in his individual capacity (Exhibit "A", ¶7).

3. Plaintiff was transported to the Gettysburg Hospital Emergency Department on or about August 27, 1999, following an altercation with correctional officers at the Adams County Prison (Id., ¶¶1-5).

4. At the Emergency Department, Plaintiff was examined and treated by Defendant Dr. Steinour (Id., ¶6).

5. As alleged, Defendant Dr. Steinour "refused to address" Plaintiff's request for anti-seizure medications and, similarly, "refused to address" Plaintiff's complaint of losing consciousness. Plaintiff contends that he has a history of epilepsy, of which Dr. Steinour was allegedly aware. Plaintiff was diagnosed and treated for multiple contusions and released to the care of Adams County Prison officials on that same date.

6. Subsequently, on August 30, 1999, Plaintiff was observed to be in a state of continued convulsions and was transported to Gettysburg Hospital Emergency Room, where he was evaluated and treated by another physician. He was admitted to Gettysburg Hospital at that time, with a diagnosis of status epilepticus.

7. Plaintiff contends that Dr. Steinour was "deliberately indifferent to his serious medical needs" in failing to treat Plaintiff as a seizure risk after being told of the epileptic condition, in violation of the Eighth Amendment of the U.S. Constitution (Id., ¶¶4(a3)). There are no State tort law claims asserted against Dr. Steinour.

8. In order to prevail under 42 U.S.C. §1983, a plaintiff must allege and prove that a defendant deprived plaintiff of his Constitutional rights while acting under color of State law. Gomez v. Toledo, 446 U.S. 635, 640 (1980).

9. Plaintiff has failed to set forth any facts of record that demonstrate that moving Defendant acted under color of State law in providing medical treatment at the Gettysburg Hospital Emergency Department. Plaintiff has, therefore, failed to state a claim under 42 U.S.C. §1983, for which relief can be granted.


10. In the alternative, and should the Court find that moving Defendant did, in fact, act under color of State law, Plaintiff has failed to set forth facts of record demonstrating that Defendant acted with deliberate indifference to his serious medical needs, as required to sustain a cause of action for denial of care under 42 U.S.C. §1983. Estelle v. Gamble, 429 U.S. 97 (1976).

11. To establish "deliberate indifference" in support of a claim for violation of civil rights, a plaintiff must establish more than negligence or inadvertent failure to provide medical care. Hampton v. Holmesburg Prison Officials, 546 F.2d 1077 (3d Cir. 1976). The Courts have recognized that where a prisoner has received some medical attention and the dispute is over the adequacy of treatment, Federal Courts are generally reluctant to second-guess medical judgments. Sturts v. City of Philadelphia, 529 F.Supp. 434 (E.D. Pa. 1982). Dismissal is appropriate as Plaintiff is unable to prove any set of facts in support of his claims which would entitle him to relief. Conley v. Gibson, 355 U.S. 41, 45-46 (1957).

WHEREFORE, Defendant William Steinour, M.D. respectfully requests that This Honorable Court grant the within Motion to Dismiss and Order that Plaintiff's claims against him be dismissed with prejudice.

Respectfully submitted,

POST & SCHELL, P.C.



Date:

JOHN R. KANTNER, ESQUIRE

ID #75741

Counsel for Defendant William J. Steinour, M.D.

Exhibit A

IN THE UNITED STATES DISTRICT COURT
FOR THE MIDDLE DISTRICT OF PENNSYLVANIA

Jason E. Benson,
Plaintiff

V.

Thomas Duran, et al.,
Defendants

: CIVIL ACTION NO. 1:CV-00-1229
:
: (Judge Caldwell)
:
: (Magistrate Judge Blevitt) ✓

9/14/00
113
FILED
SCRANTON

AMENDED COMPLAINT

FILED
SCRANTON

SEP 11 2000

PER QMB
DEPUTY CLERK

PARTIES

1.) The plaintiff, Jason E. Benson, was held at Adams County Prison (hereon A.C.P.) during the events described in this complaint.

2.) Defendant Thomas Duran is the Warden of A.C.P.. He is sued in his individual capacity.

3.) Defendants Bruce Cluck and Debra Hanky are the Deputy Wardens of A.C.P.. They are sued in their individual capacity.

4.) Defendant's John Jennings and William Orth are Lieutenants of the A.C.P.. They are sued in their individual capacity.

5.) Defendant Rae Hientzelman is a Sergeant of the A.C.P.. He is sued in his individual capacity.

6.) Defendant's Briton Shelton and David Vazquez are Correctional Officer's of the A.C.P.. They are sued in their individual capacity.

7.) Doctor William J. Steinour is a physician employed at the Gettysburg Hospital. He is sued in his individual capacity.

8. Dr. Ronald Long, physician, and Dr. William Ellien, psychiatrist, are employed at the State Correctional Institution Smithfield. They are sued in their individual capacities.

Plaintiff retains the right to amend any future Jane/John Doe defendants that becomes available through discovery.

FACTS

1.) On August 25, 1999, plaintiff, a Pennsylvania State Prisoner, was transferred to the Adams County Prison (hereafter referred to as A.C.P.) for the purpose of attending a Post Conviction Relief Act Hearing. (See Exhibit "A")

2.) On August 27, 1999, upon plaintiff's return to A.C.P. from the aforementioned hearing, he was released from the Sheriff's restrains. However, A.C.P. Intake Officer, defendant Briton Shelton, recuffed the plaintiff behind his back, and shackled him about the ankles. This not being the usual protocol for returning inmates, plaintiff inquired as to why he was being

FACTS CONTINUED FROM PAGE 2

* recuffed. Defendant Briton Shelton responded, saying, "Hey, I ain't the one!" At this time defendant Lt. John Jennings appeared, saying, "Bring Shithead in to get naked." Indicating a strip search.

* 3.) Plaintiff was led to a small room adjacent to the intake area. Plaintiff, handcuffed behind his back and shackled about the ankles, was seated in a chair. Defendant Lt. Jennings exited the room leaving plaintiff alone with defendant Briton Shelton, who was docile, and no words were exchanged. Defendant Lt. John Jennings returned with Warden Thomas Duran, Deputy Wardens Bruce Cluck and Debra Hankey, Sergeant Rae Hientzelman, and John Doe, who was carrying a video camera, filming. (See Exhibit "B" - (1), (2), and (3)).

* 4.) At this time, Deputy Warden Bruce Cluck ordered plaintiff to strip. Plaintiff, handcuffed and shackled, unable to comply, refused. Notwithstanding, plaintiff was handcuffed behind his back, and shackled about his ankles posing no threat to the defendant's, without warning was shot in the face with O.C. Pepper Foam. Plaintiff, unable to breath or see, attempted to rid himself of the O.C. Pepper Foam, lost his balance, hitting his head against a computer monitor. At this time, defendant Warden Thomas Duran gave the order to "Takem' down!" Seriously injuring plaintiff, defendants Bruce Cluck, Debra Hankey, John Jennings, Rae Hientzelman, and Briton Shelton knocked plaintiff to the ground, hammering plaintiff's head into the floor, twisting plaintiff's hands beyond normal range of motion, kicking and kneeling plaintiff in his back and side. (See Exhibit "C")

5.) After pleading for several minutes for defendant's to get off of him, defendant's relented, throwing plaintiff into a concrete shower stall, where plaintiff fell unconscious. Defendant Thomas Duran forcefully yanked plaintiff out of the shower stall, taking him to the floor again, where defendant Thomas Duran stomped his foot into the plaintiff's neck. After plaintiff was released from defendant Thomas Duran's foot, and removed of the restraints, plaintiff complied to a strip search. A.C.P. has no medical facilities, thus plaintiff requested to be taken to the Gettysburg Hospital Emergency Room. (See Exhibit "D")

* 6.) Subsequently, the Gettysburg Hospital Emergency Room physician Dr. William J. Steinour, who is familiar with plaintiff's past history of epilepsy, refused to address plaintiff's request for anti-seizure medications, as well as his complaint of losing consciousness, diagnosing the plaintiff with, "Multiple contusions" and released plaintiff to the care of A.C.P..

FACTS CONTINUED FROM PAGE 3

7.) Thereafter, on August 30, 1999, plaintiff was witnessed by defendant's Lt. William Orth and C.O. David Vazquez to be in a state of convulsions, but refused to immediately treat plaintiff until one and one-half (1½) hours later, where they again witnessed plaintiff in a state of serious convulsions, only then calling for the Adams County Sheriff's Department to transport plaintiff to the Gettysburg Hospital. Once plaintiff arrived at the Gettysburg Hospital Emergency Room, he was witnessed by hospital Medical Staff to be in a life threatening state of severe seizures known as "Status Epilepticus," incontinent, and foaming and bleeding from the mouth. Plaintiff was immediately admitted to the Gettysburg Hospital Critical Care Unit with "Imminent Death" orders (See Exhibits "E" (1), (2), (3), and (4))

8.) After further investigation, it was discovered that a series of pharmacological deviations prescribed by defendant's Dr. Ronald Long and Dr. William Ellien of SCI Smithfield precipitated into the aforementioned "Status Epilepticus" attack suffered by plaintiff. (See Exhibit "F"(4))

9.) On June 4, 1999, plaintiff was seen by defendant Dr. Ronald Long. Plaintiff complained that the anti-seizure medication he was on, (a hypantoin derivative called Dilantin) was causing unwanted side effects, and that he wanted to switch back to the anti-seizure medication he was on prior to the Dilantin. Defendant Dr. Ronald Long refused to change the medications, and abruptly discontinued plaintiff's Dilantin, without prescribing any further medications to treat plaintiff's epilepsy disorder. (See Exhibit "G")

10.) On June 15, 1999, plaintiff sent a request to defendant Dr. Ronald Long, asking him to reconsider prescribing an anti-seizure medications of any kind. This request was never responded to. (See Exhibit "H")

11.) On July 24, 1999, plaintiff was seen by defendant Dr. William Ellien, psychiatrist. At this time, plaintiff inquired as to why he wasn't on anti-seizure medications. Defendant Dr. William Ellien, said this wasn't his field of expertise and that I should talk to Defendant Dr. Ronald Long. He then prescribed the anti-depressant drug Imipramine.

12.) The abrupt discontinuance of Dilantin by defendant Dr. Ronald Long, as well as the prescription anti-depressant Imipramine, in combination with the physical and emotional trauma sustained during the use of excessive force in A.C.P. synergistically caused plaintiff to enter into the aforementioned life threatening "Status Epilepticus" seizures that occurred on August 29, 1999. (See Exhibit "I" (1), (2), and Exhibit "F(4)"

CLAIMS FOR RELIEF

1.) The actions of Warden Thomas Duran, Deputy Warden Bruce Cluck, Deputy Warden Debra Hankey, C.O. Briton Shelton, Lt. John Jennings, Sgt. Rea Heintzelman, and Jane/John Doe in using physical force against the plaintiff without need or provocation, and in failing to intervene to prevent the misuse of force was done maliciously and sadistically, and constituted cruel and unusual punishment in violation of the Eighth Amendment of the United States Constitution.

2.) Defendant's Lt. William Orth, and C.O. Vazquez's failure to provide adequate medical treatment to plaintiff, placed plaintiff in direct risk of serious injury, disease, and death constitutes deliberate indifference to the plaintiff's serious medical needs in violation of the Eighth Amendment of the United States Constitution.

3.) Adams County Prisons lack of adequately trained medical staff and medical facilities constitutes deliberate indifference to the plaintiff's serious medical needs in violation of the Eighth Amendment of the United States Constitution.

4.) Defendant Dr. William J. Stienour's failure to treat plaintiff as a seizure risk even after plaintiff explained to defendant that he was an epileptic, and not currently on medications, constitutes deliberate indifference to plaintiff's serious medical needs in violation of the Eighth Amendment of the United States Constitution.

5.) The combined actions of defendant Dr. Ronald Long and Dr. William Ellien in abruptly stopping plaintiff's anti-seizure medication and in prescribing an anti-depressant drug known to lower seizure threshold placed plaintiff in direct risk of serious injury, disease, and death constitutes deliberate indifference to plaintiff's serious medical needs in violation of the Eighth Amendment of the United States Constitution.

A2: The actions of Lt. Orth and C.O. David Vazquez in ignoring plaintiff while in seizures and post-ictal state constitutes deliberate indifference to the plaintiff's serious medical needs in violation of the Eighth Amendment of the United States Constitution.

A3: The actions of Dr. William J. Steinour in refusing to treat plaintiff as a seizure risk, despite plaintiff reminding him that he was epileptic and not currently on anti-seizure medication constitutes deliberate indifference in violation of the

CLAIMS FOR RELIEF
CONTINUED FROM PAGE 5

Eighth Amendment of the United States Constitution.

A5: The actions of Dr. Ronald Long in abruptly discontinuing plaintiff's anti-seizure medications despite foreknowledge that such actions would cause severe, life threatening seizures constitutes deliberate indifference in violation of the Eighth Amendment of the United States Constitution.

A6: The actions of defendant Dr. William Ellien in prescribing the drug Tofranil known to decrease the seizure threshold, with foreknowledge that plaintiff was epileptic and had been abruptly withdrawn from his anti-seizure medications and the seizure risk associated with the withdrawal of said medications and the addition of the drug Tofranil he prescribed constitutes deliberate indifference to the Eighth Amendment of the United States Constitution.

B-2: \$500,000.00 against Dr. Ronald Long and Dr. William Ellien for abruptly discontinuing plaintiff's anti-seizure medication and prescribing an anti-depressant seizure antagonist drug, and causing plaintiff to fall into a life threatening state of seizures known as "Status Epilepticus," and subsequent hospitalization of plaintiff.

PHYSICIAN'S ORDER

Exhibit G

Inmate Name: Jason Benson

Inmate Number: DS 6483

DOB: 9-27-76

Institution: Smithfield C

Drug Allergies:

NKA

Self-Medication Program ☐ Yes ☒ No

Date/ Military Time	Prob #	DO NOT USE THIS SHEET UNLESS A RED NUMBER SHOWS	1
7-27-99	B	① Next appointment in 1 month.	
1605 hrs		② Ativan 1mg PO q 6 hrs PRN anxiety, stat: max 2 doses/day; max 6 doses/week; for 1 month.	
		③ Begin Imipramine 50mg PO qd daily, through 3 Aug '99.	
		④ On 4 Aug '99 - increase Imipramine to 75mg PO qd, daily, through 10 Aug 1999.	
		⑤ On 11 Aug '99 - increase Imipramine to 100mg PO qd, daily, for 5 months.	
		⑥ On/about 19 Aug 1999 - obtain Trazodone (Imipramine + desipramine) 1200mg qd in AM.	
		a) Administered 1200mg	
		Medical Ltr 7/27/99 2000	
		Barb Grove, L.P.N.	
		This information is strictly Received CONFIDENTIAL and is for the use of only the person or JUL 27 1999 agency in whom it is addressed. These reports are not to be SCI-Smitment available to any person Medical Records Department	
		JUL 27 1999 SCI-SMITFIELD Medical Records Dept.	

PLEASE USE BALL POINT PEN ONLY

1730

Physicians' Desk Reference®

Consult 1994 Supplement

Parke-Davis—Cont.

COLY-MYCIN® S OTIC

[cō'ly-my'cīn s ō'tic]

with Neomycin and Hydrocortisone
(colistin sulfate—neomycin
sulfate—thonzonium
bromide—hydrocortisone acetate
otic suspension)

DESCRIPTION

Coly-Mycin S Otic with Neomycin and Hydrocortisone (colistin sulfate-neomycin sulfate-thonzonium bromide-hydrocortisone acetate otic suspension) is a sterile aqueous suspension containing in each ml: Colistin base activity, 3 mg (as the sulfate); Neomycin base activity, 3.3 mg (as the sulfate); Hydrocortisone acetate, 10 mg (1%); Thonzonium bromide, 0.5 mg (0.05%); Polysorbate 80, acetic acid, and sodium acetate in a buffered aqueous vehicle. Thimerosal (mercury derivative), 0.002%, added as a preservative. It is a non-viscous liquid, buffered at pH 5, for instillation into the canal of the external ear or direct application to the affected aural skin.

CLINICAL PHARMACOLOGY

1. Colistin sulfate—an antibiotic with bactericidal action against most gram-negative organisms, notably *Pseudomonas aeruginosa*, *E. coli*, and *Klebsiella-Aerobacter*.
2. Neomycin sulfate—a broad-spectrum antibiotic, bactericidal to many pathogens, notably *Staph aureus* and *Proteus* sp.
3. Hydrocortisone acetate—a corticosteroid that controls inflammation, edema, pruritus and other dermal reactions.
4. Thonzonium bromide—a surface-active agent that promotes tissue contact by dispersion and penetration of the cellular debris and exudate.

INDICATIONS AND USAGE

For the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.

CONTRAINDICATIONS

This product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia and varicella.

WARNINGS

As with other antibiotic preparations, prolonged treatment may result in overgrowth of nonsusceptible organisms and fungi.

If the infection is not improved after one week, cultures and susceptibility tests should be repeated to verify the identity of the organism and to determine whether therapy should be changed.

Patients who prefer to warm the medication before using should be cautioned against heating the solution above body temperature, in order to avoid loss of potency.

PRECAUTIONS

General: If sensitization or irritation occurs, medication should be discontinued promptly.

This drug should be used with care in cases of perforated eardrum and in longstanding cases of chronic otitis media because of the possibility of ototoxicity caused by neomycin. Treatment should not be continued for longer than ten days. Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin.

ADVERSE REACTIONS

Neomycin is a not uncommon cutaneous sensitizer. There are articles in the current literature that indicate an increase in the prevalence of persons sensitive to neomycin.

DOSAGE AND ADMINISTRATION

The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator.

When using the calibrated dropper:

For adults, 5 drops of the suspension should be instilled into the affected ear 3 or 4 times daily. For infants and children, 4 drops are suggested because of the smaller capacity of the ear canal.

This dosage correlates to the 4 drops (for adults) and 3 drops (for children) recommended when using the dropper-bottle container for this product.

The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and

4 hours. The wick should be replaced at least once every 24 hours.

HOW SUPPLIED

Coly-Mycin S Otic is supplied as:

N 0071-3141-35—5-mL bottle with dropper

N 0071-3141-36—10-mL bottle with dropper

Each ml contains: Colistin sulfate equivalent to 3 mg of colistin base, Neomycin sulfate equivalent to 3.3 mg neomycin base, Hydrocortisone acetate 10 mg (1%), Thonzonium bromide 0.5 mg (0.05%), and Polysorbate 80 in an aqueous vehicle buffered with acetic acid and sodium acetate. Thimerosal (mercury derivative) 0.002% added as a preservative.

Shake well before using.

Store at controlled room temperature 15°–30°C (59°–86°F). Stable for 18 months at room temperature; prolonged exposure to higher temperatures should be avoided.

3141G033

Caution—Federal law prohibits dispensing without prescription.

KAPSEALS®**DILANTIN®**

[dī-lān'tin "]

(Extended Phenytoin Sodium Capsules, USP)

DESCRIPTION

Phenytoin Sodium is an antiepileptic drug. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is sodium 5,5-diphenyl-2,4-imidazolidinedione.

Each Dilantin—Extended Phenytoin Sodium Capsule USP contains 30 mg or 100 mg phenytoin sodium USP. Also contains lactose, NF; sucrose, NF; talc, USP; and other ingredients. The capsule shell and band contain colloidal silicon dioxide, NF; FD&C red No. 3; gelatin, NF; glyceryl monooleate; sodium lauryl sulfate, NF. The Dilantin 30-mg capsule shell and band also contain citric acid, USP; FD&C blue No. 1; sodium benzoate, NF; titanium dioxide, USP. The Dilantin 100-mg capsule shell and band also contain FD&C yellow No. 6; hydrogen peroxide 3%; polyethylene glycol 200. Product *in vivo* performance is characterized by a slow and extended rate of absorption with peak blood concentrations expected in 4 to 12 hours as contrasted to *Prompt Phenytoin Sodium Capsules* USP with a rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours.

CLINICAL PHARMACOLOGY

Phenytoin is an antiepileptic drug which can be useful in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Possibly by promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of posttetanic potentiation at synapses. Loss of posttetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures.

The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours. Steady-state therapeutic levels are achieved 7 to 10 days after initiation of therapy with recommended doses of 300 mg/day.

When serum level determinations are necessary, they should be obtained at least 5-7 half-lives after treatment initiation, dosage change, or addition or subtraction of another drug to the regimen so that equilibrium or steady-state will have been achieved. Trough levels provide information about clinically effective serum level range and confirm patient compliance and are obtained just prior to the patient's next scheduled dose. Peak levels indicate an individual's threshold for emergence of dose-related side effects and are obtained at the time of expected peak concentration. For Dilantin Kapseals peak serum levels occur 4-12 hours after administration.

Optimum control without clinical signs of toxicity occurs more often with serum levels between 10 and 20 mcg/ml, although some mild cases of tonic-clonic (grand mal) epilepsy may be controlled with lower-serum levels of phenytoin.

In most patients maintained at a steady dosage, stable phenytoin serum levels are achieved. There may be wide interpatient variability in phenytoin serum levels with equivalent dosages. Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin. Unusually high levels result from liver disease, congenital enzyme deficiency or drug interactions which result in metabolic interference. The patient with large variations in phenytoin plasma levels, despite standard doses, presents a difficult clinical prob-

free phenytoin levels may be altered in patients with abnormal protein binding characteristics differ from normal. Most of the drug is excreted in the bile and feces which are then reabsorbed from the intestine and excreted in the urine. Urinary excretion of metabolites occurs partly with glomerular filtration and more importantly, by tubular secretion. Phenytoin is hydroxylated in the liver by an enzyme which is saturable, small incremental doses may result in substantial increases in serum levels, when the dosage is increased. The steady-state level may be increased, with resultant intoxication, from a dosage of 10% or more.

INDICATIONS AND USAGE

Dilantin is indicated for the control of tonic-clonic (grand mal and temporal lobe) seizures and prevention and treatment of seizures occurring after neurosurgery.

Phenytoin serum level determinations may be useful for optimal dosage adjustments (see Dosage Administration).

CONTRAINDICATIONS

Phenytoin is contraindicated in those patients hypersensitive to phenytoin or other hydantoin derivatives.

WARNINGS

Abrupt withdrawal of phenytoin in epileptic patients precipitates status epilepticus. When, in the opinion of the clinician, the need for dosage reduction, discontinuation or substitution of alternative antiepileptic therapy should be done gradually. However, in patients with allergic or hypersensitivity reaction, rapid discontinuation of alternative therapy may be necessary. In such cases, alternative therapy should be an antiepileptic drug of the hydantoin chemical class.

There have been a number of reports suggesting a relationship between phenytoin and the development of lymphadenopathy (local or generalized) including hyperplasia, pseudolymphoma, lymphoma, and leukemia.

Although a cause and effect relationship has not been established, the occurrence of lymphadenopathy in patients receiving phenytoin need to differentiate such a condition from lymph node pathology. Lymph node involvement with or without symptoms and signs resembling infectious disease, eg, fever, rash and liver involvement. In all cases of lymphadenopathy, follow-up with an extended period is indicated and every effort should be made to achieve seizure control using alternative drugs.

Acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels. In view of isolated reports associating phenytoin with porphyria, caution should be exercised in its use in patients suffering from porphyria.

Usage in Pregnancy: A number of reports suggests an association of antiepileptic drugs by women with epileptic seizures and incidence of birth defects in children born to them. Data are more extensive with respect to phenytoin, but these are also the most common antiepileptic drugs; less systematic or anecdotal reports suggest a possible similar association with the use of other antiepileptic drugs.

The reports suggesting a higher incidence of children of drug-treated epileptic women cases as adequate to prove a definite cause and effect. There are intrinsic methodologic problems in the interpretation of data on drug teratogenicity in humans and the epileptic condition itself may be more of a confounding factor in leading to birth defects. The reports of the mothers on antiepileptic medication during pregnancy. It is important to note that antiepileptic drugs should not be discontinued in patients in whom they are administered to prevent major seizures, the strong possibility of precipitating status epilepticus, attendant hypoxia and threat to life. In patients where the severity and frequency of the seizures are such that the removal of medication does not pose a threat to the patient, discontinuation of the drug should be considered prior to and during pregnancy. It should not be said with any confidence that even the most careful prescribing physician will wish to weigh the risks of continuing antiepileptic therapy in treating and counseling epileptic childbearing potential.

In addition to the reports of increased incidence of malformations, such as cleft lip/palate and other congenital anomalies in children of women receiving phenytoin, there have been more recent reports of a fetal hydantoin syndrome. This consists of facial dysmorphism, microcephaly and mental deficiency.

Skin rash, petechiae, urticaria, itching, photosensitivity, edema (general or of face and tongue); drug fever; activity with desipramine.

Bone marrow depression including agranulocytosis, leukopenia, purpura; thrombocytopenia.

Intestinal: Nausea and vomiting, anorexia, epigastric pain, diarrhea; peculiar taste, stomatitis, abdominal black tongue.

Gynecomastia in the male; breast enlargement in the female; increased or decreased libido; testicular swelling; elevation or depression of sugar levels; inappropriate antidiuretic hormone secretion syndrome.

Jaundice (simulating obstructive); altered liver weight gain or loss; perspiration; flushing; urinary frequency; drowsiness, dizziness, weakness and fatigue; parotid swelling; alopecia; proneness to falling.

General Symptoms: Though not indicative of addiction, cessation of treatment after prolonged therapy may cause nausea, headache and malaise.

USE AND ADMINISTRATION

Up to 100 mg/day intramuscularly in divided doses. Intramuscular administration should be used only for starting patients unable or unwilling to use oral medication. The oral form should supplant the injectable as soon as possible.

Dosages are recommended for elderly patients and patients. Lower dosages are also recommended for outpatients compared to hospitalized patients who will be under supervision. Dosage should be initiated at a low level and increased gradually, noting carefully the clinical response and any evidence of intolerance. Following remission, maintenance medication may be required for a longer period of time, at the lowest dose that will maintain remission.

OVERDOSAGE

Patients have been reported to be more sensitive than adults to overdosage of imipramine hydrochloride. An overdose of any amount in infants or young children, if not treated, must be considered serious and potentially fatal.

Symptoms: These may vary in severity depending on factors such as the amount of drug absorbed, the patient, and the interval between drug ingestion and start of treatment. Blood and urine levels of imipramine do not reflect the severity of poisoning; they have qualitative rather than quantitative value, and are not indicators in the clinical management of the patient.

Abnormalities may include drowsiness, stupor, coma, weakness, agitation, hyperactive reflexes, muscularity, ataxia and choreiform movements, and convulsions.

Abnormalities may include arrhythmia, tachycardia, evidence of impaired conduction, and signs of conduction block.

Other symptoms include depression, cyanosis, hypotension, shock, vomiting, pyrexia, mydriasis, and diaphoresis may also be present.

The recommended treatment for overdosage of imipramine antidepressants may change periodically. It is recommended that the physician contact a poison control center for current information on treatment.

CNS involvement, respiratory depression and cardiac arrhythmia can occur suddenly, hospitalization and intensive care may be necessary, even when the amount ingested is thought to be small or the initial degree of intoxication appears slight or moderate. All patients with ECG abnormalities should have continuous cardiac monitoring closely observed until well after cardiac status has returned to normal; relapses may occur after apparent recovery.

For patient, empty the stomach promptly by lavage. For intubated patient, secure the airway with a cuffed endotracheal tube before beginning lavage (do not induce emesis). Administration of activated charcoal slurry may help reduce absorption of imipramine.

External stimulation to reduce the tendency to hyperventilate. If anticonvulsants are necessary, diazepam and phenytoin may be useful.

Ensure adequate respiratory exchange. Do not use respiratory stimulants.

Patients should be treated with supportive measures, such as oxygenation, intravenous fluids, and, if necessary, a vasopressor. The use of corticosteroids in shock is contraindicated. The use of corticosteroids in shock is contraindicated in cases of overdosage of imipramine antidepressants. Digitalis may increase conduction and further irritate an already sensitized myocardium. If congestive heart failure necessitates rapid diuresis, particular care must be exercised.

Patients should be controlled by whatever external means available, including ice packs and cooling sponge blankets.

Peritoneal dialysis, exchange transfusions and hemodialysis have been generally reported as ineffective.

because of the rapid fixation of imipramine in tissues. Blood and urine levels of imipramine may not correlate with the degree of intoxication, and are unreliable indicators in the clinical management of the patient.

The slow intravenous administration of physostigmine salicylate has been used as a last resort to reverse severe CNS anticholinergic manifestations of overdosage with tricyclic antidepressants; however, it should not be used routinely, since it may induce seizures and cholinergic crises.

HOW SUPPLIED

Ampuls 2 ml—For intramuscular administration only
25 mg imipramine hydrochloride, 2 mg ascorbic acid, 1 mg sodium bisulfite, 1 mg sodium sulfite

Boxes of 10NDC 0028-0065-23
Store between 59°-86°F (15°-30°C).

Note: Upon storage, minute crystals may form in some ampuls. This has no influence on the therapeutic efficacy of the preparation, and the crystals redissolve when the affected ampuls are immersed in hot tap water for 1 minute.

ANIMAL PHARMACOLOGY & TOXICOLOGY

A. Acute: Oral LD₅₀ ranges are as follows:

Rat 355 to 682 mg/kg
Dog 100 to 215 mg/kg

Depending on the dosage in both species, toxic signs proceeded progressively from depression, irregular respiration and ataxia to convulsions and death.

B. Reproduction/Teratogenic: The overall evaluation may be summed up in the following manner:

Oral: Independent studies in three species (rat, mouse and rabbit) revealed that when Tofranil is administered orally in doses up to approximately 2½ times the maximum human dose in the first 2 species and up to 25 times the maximum human dose in the third species, the drug is essentially free from teratogenic potential. In the three species studied, only one instance of fetal abnormality occurred (in the rabbit) and in that study there was likewise an abnormality in the control group. However, evidence does exist from the rat studies that some systemic and embryotoxic potential is demonstrable. This is manifested by reduced litter size, a slight increase in the stillborn rate and a reduction in the mean birth weight.

Parenteral: In contradistinction to the oral data, Tofranil does exhibit a slight but definite teratogenic potential when administered by the subcutaneous route. Drug effects on both the mother and fetus in the rabbit are manifested in higher resorption rates and decrease in mean fetal birth weights, while teratogenic findings occurred at a level of 5 times the maximum human dose. In the mouse, teratogenicity occurred at 1½ and 6½ times the maximum human dose, but no teratogenic effects were seen at levels 3 times the maximum human dose. Thus, in the mouse, the findings are equivocal.

C91-42 (Rev. 2/92)

Dist. by:
Geigy Pharmaceuticals
Ciba-Geigy Corporation
Ardley, New York 10502

TOFRANIL®

[toe-fray 'nill]

Imipramine hydrochloride USP

Tablets of 10 mg

Tablets of 25 mg

Tablets of 50 mg

For oral administration

DESCRIPTION

Tofranil, imipramine hydrochloride USP, the original tricyclic antidepressant, is a member of the dibenzazepine group of compounds. It is designated 5-[3-(Dimethylamino)propyl]-10, 11-dihydro-5H-dibenz[b,f] azepine Monohydrochloride. Imipramine hydrochloride USP is a white to off-white, odorless, or practically odorless crystalline powder. It is freely soluble in water and in alcohol, soluble in acetone, and insoluble in ether and in benzene. Its molecular weight is 316.87. **Inactive Ingredients:** Calcium phosphate, cellulose compounds, docusate sodium, iron oxides, magnesium stearate, polyethylene glycol, povidone, sodium starch glycolate, sucrose, talc and titanium dioxide.

CLINICAL PHARMACOLOGY

The mechanism of action of Tofranil is not definitely known. However, it does not act primarily by stimulation of the central nervous system. The clinical effect is hypothesized as being due to potentiation of adrenergic synapses by blocking uptake of norepinephrine at nerve endings. The mode of action of the drug in controlling childhood enuresis is thought to be apart from its antidepressant effect.

INDICATIONS

Depression: For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other

depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident.

Childhood Enuresis: May be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. In patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. The effectiveness of treatment may decrease with continued drug administration.

CONTRAINDICATIONS

The concomitant use of monoamine oxidase inhibiting compounds is contraindicated. Hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. The potentiation of adverse effects can be serious, or even fatal. When it is desired to substitute Tofranil in patients receiving a monoamine oxidase inhibitor, as long an interval should elapse as the clinical situation will allow, with a minimum of 14 days. Initial dosage should be low and increases should be gradual and cautiously prescribed.

The drug is contraindicated during the acute recovery period after a myocardial infarction. Patients with a known hypersensitivity to this compound should not be given the drug. The possibility of cross-sensitivity to other dibenzazepine compounds should be kept in mind.

WARNINGS

Children: A dose of 2.5 mg/kg/day of Tofranil should not be exceeded in childhood. ECG changes of unknown significance have been reported in pediatric patients with doses twice this amount.

Extreme caution should be used when this drug is given to patients with cardiovascular disease because of the possibility of conduction defects, arrhythmias, congestive heart failure, myocardial infarction, strokes and tachycardia. These patients require cardiac surveillance at all dosage levels of the drug.

patients with increased intraocular pressure, history of urinary retention, or history of narrow-angle glaucoma because of the drug's anticholinergic properties; hyperthyroid patients or those on thyroid medication because of the possibility of cardiovascular toxicity; patients with a history of seizure disorder because this drug has been shown to lower the seizure threshold; patients receiving guanethidine, clonidine, or similar agents, since Tofranil may block the pharmacologic effects of these drugs;

patients receiving methylphenidate hydrochloride. Since methylphenidate hydrochloride may inhibit the metabolism of Tofranil, downward dosage adjustment of imipramine hydrochloride may be required when given concomitantly with methylphenidate hydrochloride.

Tofranil may enhance the CNS depressant effects of alcohol. Therefore, it should be borne in mind that the dangers inherent in a suicide attempt or accidental overdosage with the drug may be increased for the patient who uses excessive amounts of alcohol. (See PRECAUTIONS.) Since Tofranil may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as operating an automobile or machinery, the patient should be cautioned accordingly.

PRECAUTIONS

An ECG recording should be taken prior to the initiation of larger-than-usual doses of Tofranil and at appropriate intervals thereafter until steady state is achieved. (Patients with any evidence of cardiovascular disease require cardiac surveillance at all dosage levels of the drug. See WARNINGS.) Elderly patients and patients with cardiac disease or a prior history of cardiac disease are at special risk of developing the cardiac abnormalities associated with the use of Tofranil.

It should be kept in mind that the possibility of suicide in seriously depressed patients is inherent in the illness and may persist until significant remission occurs. Such patients should be carefully supervised during the early phase of treatment with Tofranil, and may require hospitalization. Prescriptions should be written for the smallest amount feasible.

Hypomanic or manic episodes may occur, particularly in patients with cyclic disorders. Such reactions may necessitate discontinuation of the drug. If needed, Tofranil may be resumed in lower dosage when these episodes are relieved. Administration of a tranquilizer may be useful in controlling such episodes.

An activation of the psychosis may occasionally be observed in schizophrenic patients and may require reduction of dosage and the addition of a phenothiazine.

Concurrent administration of Tofranil with electroshock therapy may increase the hazards; such treatment should be

Continued on next page

The full prescribing information for each Geigy product is contained herein and is that in effect as of September 1, 1993.

1 IN THE COURT OF COMMON PLEAS OF ADAMS COUNTY, PENNSYLVANIA

2 Criminal

3 Commonwealth

4 vs.

CC-510-98

5 Jason Eric Benson

6 ORDER OF COURT

7 AND NOW, this 27th day of August, 1999, the
8 Defendant appeared with counsel. Counsel has indicated that
9 she has filed an amended PCRA petition, which raises one
10 issue which is legal in nature. The argument is that the
11 Court is without power to impose two separate sentences on
12 count five and six in that there should have been only one
13 conspiracy.

14 IT IS ORDERED that a transcript be prepared of the
15 proceedings that occurred on August 4, 1998 and filed of
16 record. Copies will be provided counsel at the initial cost
17 of the County of Adams.

18 Argument is scheduled for November 30, 1999 at
19 9:00 a.m. PCRA counsel shall file her brief by
20 November 9, 1998, and the Commonwealth shall file its brief
21 by November 17, 1999.

22 By the Court,

23
24
25 Michael A. George, Esq., DA
Kristen L. Rice, Esq.

Oscar F. Spicer
President Judge

COPY

page 1
ACPF #

ADAMS COUNTY PRISON

EXTRAORDINARY OCCURRENCE REPORT

NAME Benson, Jason ACP# 99-00740 DATE 8/27/99
 HOUSING AREA A-Block LOCATION OF INCIDENT Intake
 TIME: 1120

Brief Summary of Incident:

(Include Staff and Inmate Names and Number) On above time & date I, Sgt Hentel was asked to help with Inmate Benson, Jason at intake. Inmate Benson, Jason did not want to strip after count.

Action and Comments: Taken to Counseling Rm. 1710 for EVALUATION
AS A RESULT OF THE O.C. AND THE DUMFRIES REQUEST
P.S.P. ADVISED & COT'S CHARGED CHARGES
FOR ABUSEMENT ASSISTED BY A PRISONER
EVENT WAS VIDEO TAPED

Shift Commander

Signature and I.D. No.: [Signature] Date and Time 8/27/99 1600

Print Name LT. Tenebr

Report of Incident: On above time & date I, Sgt Hentel was asked to help with Inmate Benson, Jason in the Intake area. Inmate Benson was having a problem that he didn't want to be strip after coming back from court. He was asked to strip but he refused to do so. At that time he was sprayed & then he started to hit his head on the computer screen. After this he wouldn't stop so he was taken to the floor until he had enough & then he was placed in the shower.

(over for continuation)

Signature

I.D. No.: Sgt Hentel 61-4 Date and Time 8/27/99 1300

Name

Heintzelman

Exhibit 8 ACP#
Page 2ADAMS COUNTY PRISON
EXTRAORDINARY OCCURRENCE REPORTNAME Benson, Jason ACP# 99-0740 DATE 8/27/99
HOUSING AREA A-Block LOCATION OF INCIDENT Medical Office
TIME: 1145 hrs

Brief Summary of Incident:

(Include Staff and Inmate Names and Number) Use of forceAction and Comments: Inmate showered, transferred to E-Block and transported to ER and
examined by the on-duty physician.PSP notified to press charges.* Incident was video documented

Shift Commander

Signature and I.D. No.:

B.A. Cluck

Date and Time

8/27/99 1500 hrs

Print Name

B.A. CluckReport of Incident: On the above time and date, I was informed by Lt Jennings that the
aforementioned inmate was refusing to submit to a strip-search upon returning from
court. I attempted to speak w/ Inmate Benson about his actions but he only began
telling profanities and making comments like, "Fuck this! This is fucking Bullshit! I'm
it stripping!" He was again asked to cooperate and submit to a search and he
again refused. At that point, Lt Jennings sprayed a one second burst of OC spray (Foam)
into Benson face. Benson then began calling staff present, "fucking animals," "cock suckers"
(over for continu

off Signature

id I.D. No.:

B.A. Cluck

Date and Time

8/27/99 1500 hrs

Print Name

B.A. Cluck

ADAMS COUNTY PRISON
EXTRAORDINARY OCCURRENCE REPORT

NAME BENSON, JASON ACP# 990740 DATE 8/27/99
HOUSING AREA E-2 LOCATION OF INCIDENT MEDICAL ROOM
TIME: 11:10

Brief Summary of Incident:


(Include Staff and Inmate Names and Number)

FORCE USED ON INMATE BENSON
JASON (990740). WARDEN DURAN, DEPUTY WARDENS CLUC
AND HANKEY, LT. JENNINGS, SGT. HEINTZELMAN,
OFFICER SHATAN

Action and Comments: TAKEN TO E.R. @ 1310 FOR MEDICAL ATTENTION
AS A RESULT OF O.C. AND INMATE'S REQUEST.
DSP NOTIFIED TO FILE CRIMINAL CHARGES
FOR AGGRAVATED ASSAULT BY PRISONER.
ENTIRE EVENT WAS VIDEO-TAPED.

Shift Commander

Signature and I.D. No.:

Date and Time 8-27-99 NOW

Print Name

Lt. Jennings

Report of Incident: ON THE ABOVE DATE & APP. TIME, LT. JENNINGS
INFORMED ME THAT INMATE BENSON, UPON HIS RETURN
FROM COURT WAS REFUSING TO BE STRIP-SEARCHED.
I REPORTED TO THE LT'S. OFFICE AND MET LT.
JENNINGS WHO BRIEFED ME ON WHAT HAD TRANSPIRED
THUS FAR. A PLAN WAS DEVISED AND WE REPORTED
TO THE MEDICAL ROOM, WHERE DEPUTY WARDEN

(over for continuation)

Shift Commander

Signature and I.D. No.:



Date and Time

8/27/993:10 PM

Print Name

DURAN

4. STATUS		PHOTO UNIT RECORD	
<input checked="" type="checkbox"/> EVIDENCE <input type="checkbox"/> FOUND <input type="checkbox"/> RECOVERED <input type="checkbox"/> RECEIPT <input type="checkbox"/> OTHER	5. OFFENSE AGG. Assault on Person		
7. SUBMITTING OFFICER	8. RECEIVING OFFICER		
BADGE NO.	BADGE NO.		
	9. DATE		
	TIME		
	6. STATION/DISTRICT OFFICE Glenview 2111		

12. FOUND OR RECOVERED FROM SIGNATURE	ADDRESS	TELEPHONE NO.	LOCATION	13. DATE	TIME
WINGOLD	1100 AS BUREAU	ACB 625	BIRMINGHAM CO. CONFERENCE TRUL	09/21/15	1:00

STORAGE AREA	DISPOSITION	REMOVAL CODE
1. PROPERTY ROOM	1. DESTROYED	1. CUSTODY
2. SAFETY DEPOSIT BOX	2. ESCHEATABLE	2. COURT
3. EXPLOSIVE MAGAZINE	3. EXPENDED IN LABORATORY	3. LABORATORY
4. NON-DEPARTMENT	4. RELEASED TO OWNER/FINDER	4. OTHER
	5. DONATED	

5.	ITEMS - (ONE ITEM PER LINE)	16. TYPE PROPERTY	17. CODE	18. QUANTITY	19. VALUE	20. STORAGE AREA CODE	21. DISPOSITION CODE

2	2011 SEA 1415 V.03, MAGGIORE JASON BRISSEN	27	01	1		
---	--	----	----	---	--	--

3						
---	--	--	--	--	--	--

4					
5					

9							
---	--	--	--	--	--	--	--

7						
8						

[illegible][illegible]

DATE & TIME	ITEM(S) NO.	OFFICER'S SIGNATURE - BADGE NO.	OFFICERS INIT. BADGE NO.	REMOVAL CODE & LOCATION	DATE OF RETURN	COMPUTER ENTRY
2/21/05 11:00	1	[Signature]	[Signature]			

[illegible][illegible][illegible][illegible]

CLAIMANT'S SIGNATURE	OWNER'S SIGNATURE	DATE
----------------------	-------------------	------

THE GETTYSBURG HOSPITAL

EMERGENCY DEPARTMENT REPORT

NAME: BENSON, JASON E
MR: 177556

DATE OF VISIT: 08/27/1999

HISTORY: This 22 year old presents to the Emergency Department in handcuffs and ankle cuffs for evaluation of injuries sustained in a "scuffle" with the prison guards. The patient states that he was "man handled" by the prison guards, was taken down, and felt like he was being kicked, although he was maced at the time and couldn't really see how he was being taken down. He complains of numbness in his knuckles, pain in his back and chest, and in the back of his head. His last tetanus booster was about a month ago.

MEDICATIONS: Ativan once daily. Had a dose earlier this morning. Feels stressed out right now and wants more Ativan.

PHYSICAL: The patient is awake, alert, appears in no acute or severe distress although he appears apprehensive. He is afebrile. Blood pressure is 132/90, pulse 92, respirations 20 and not labored.

HEENT

Reveals superficial contusion of the right frontotemporal scalp. No other scalp injury is noted. He has conjunctival injection. Tympanic membranes are normal. Pupils are equal and react normally. EOM's intact. There is no facial asymmetry. Speech is normal. There is no tenderness of his neck. There is no apparent pain with neck motion. He has tenderness to palpation of the paraspinous lumbar muscles. He has point tenderness over the right inferolateral thorax. He has no pain in that area with AP compression of his chest. There is no crepitus noted.

LUNGS

Clear and equal and he is breathing deeply and ventilating well.

ABDOMEN

Soft and nontender.

EXTREMITIES

Lower extremity exam is normal. Exam of the upper extremity reveals a few superficial handcuff type contusions of the skin. His neuro exam to the upper extremities is normal. Capillary refill is intact. Sensation and color is normal.

TREATMENT/PLAN: The patient is given 1 mg of Ativan by mouth, released in the care of the prison guards, and is to follow with Dr. Posner. He is to be given Tylenol as needed for discomfort.

IMPRESSION: Multiple contusions.

WJS:dlh
DD 08/27/1999 DT 08/27/1999 14 17

SIGNED BY WILLIAM J STEINOUR, MD

Exhibit F

Page 1

THE GETTYSBURG HOSPITAL**EMERGENCY DEPARTMENT REPORT**

NAME: BENSON, JASON E
MR: 177556

8-310
DATE OF VISIT: 08/30/1999

CHIEF COMPLAINT Seizure

HISTORY: The sheriff that transported this patient from prison says he was told that this patient had a small seizure about an hour and a half ago and then a larger one more recently that prompted the decision to transport this gentleman to the Emergency Department. He was noted to be bleeding from his mouth following the second seizure. He was apparently transported to the Emergency Department in the police cruiser in a conscious condition but shortly after arriving here, had another seizure which occurred in our parking lot area. This was observed by paramedic staff and was observed to be significant. When I went out to the parking lot area, he was noted to be apparently post ictal with bloody mucous coming from his mouth. His respirations were somewhat labored. He was transported into the Emergency Department for further evaluation.

PAST MEDICAL HISTORY Positive for seizures in the past. He has been worked up with neurology consults, numerous CT's and I believe EEG. It is believed he has a seizure disorder although he apparently had seizures prompted or precipitated by his multi drug use which includes cocaine, marijuana, and ecstasy. He was seen here a couple of days ago by Dr. Steimour for injuries related to a scuffle with prison guards. He apparently was maced at that point but was treated and released with a diagnosis of multiple contusions.

MEDICATIONS Faxed to us from prison are Serzone, Ativan p r n and Imipramine. He apparently is on no anticonvulsants.

PHYSICAL: On arrival in the Emergency Department the patient is pale, diaphoretic, unresponsive with somewhat snoring respirations. O2 saturation initially was about 88% range. He was somewhat resistant to maintaining oxygen mask on his face but as he became more lucid he became calmer and his O2 saturation improved into the high 90's. Within the period of 15 minutes or so in our department, he was able to look towards me in response to his name being called and able to follow simple commands such as opening his mouth.

HEENT	He has a little minor ecchymosis in his left postauricular area. Pupils are equal. TM's, nares unremarkable. Exam of his mouth I believe shows an abrasion of the right lateral tongue.
NECK	Appears to be supple.
LUNGS	Clear anteriorly.
HEART	Regular rhythm.
ABDOMEN	Soft.
EXTREMITIES	He was initially wearing handcuffs but was switched to leg shackles by the sheriff that brought him in. He seems to have movement in all his arms and legs.

TREATMENT/PLAN: Since this seizure witnessed by us in the Emergency Department was his third in a short period of time, he was given a loading dose of Dilantin 1 gram IV. Blood work has been drawn which shows a white count of 17.6 with a normal H&H and platelet count. Chem panel 2 is pending.

THE GETTYSBURG HOSPITAL

EMERGENCY DEPARTMENT REPORT

NAME: BENSON, JASON E
MR: 177556

I plan to speak to the next doctor up for unassigned admission about this patient With three seizures in a short period of time, I feel that he should be admitted to the hospital for more close observation

IMPRESSION: Multiple seizures

TWH dli
DD 08/30/1999 DT 09/01/1999 11 34


 9/2/99
SIGNED BY TIMOTHY W HOLLAND, MD

EXHIBIT F 10/10/00

THE GETTYSBURG HOSPITAL

CONSULTATION REPORT

0300410351 17-75-56

NAME JASON BENSON

FENSON, JASON E
KANSLER, DAVID F MD

DATE AND TIME OF REQUEST 30/06/99 0900

EZC7A 09/27/1976 22Y

TO DOCTOR DR MESSER

OPINION
ONLYTREAT AND
FOLLOW

REASON FOR CONSULTATION:

RECURRENT SEIZURES

REQUESTING PHYSICIAN: DR KANSLER

DATE
30/06/99TIME
0910

SIGNATURE DR KANSLER

PERSON NOTIFIED
OF REQUEST

DEB

REPORT OF CONSULTATION (Findings, Diagnosis, Recommendations)

22Y.O WM WITH NO EPILEPSY SINCE 12 Y.O. P.H. OF "PETIT MAL" (PROBABLY COMPLEX-PARTIAL SEIZURES) + GENERALIZED. EEG'S 3/89 + 4/90 → (1) TEMPORAL FOCUS EEG 8/97 @ 2 AM FOR SEIZURES 2° TO PT. DIC OF DILANTIN + DRUG USE. CLOMIDRONE A SERZONE, ANIVAN, IMPRAMINE PTA FROM G.P. SON. R (V. DILANTIN + GM. LAB OK BUT TWBC ↓ CO₂ CW POST-ICUTAL STATE. HAD TII SZ THIS AM 0440 → OWSE IN SLEEP DICKED DILANTIN X 4 MOS

EXAM: NECK SUPPLE. M.S. - ALERT + ORIENTED. NO APHASIA. MEMORY OK. CN - VIS FIELDS ✓ FUNDUS ✓ NO PROLIFER. PERR. ENT - FAIR. SM ✓ ⊕ NYSTAGMUS IN ALL DIRECTIONS (CW DILANTIN LOADING) HEART - TONGUE ✓ MOTOR - NO DRUG POWER R=L TONE ✓ SEVS ✓ DTR'S 1-L+R=L TOES M

EEG - TODAY → (1) DISCHARGE IMP. (2) SEIZURE DISORDER, (3) STATUS EPILEPTICUS @ 2 AM 2° TO DIC OF DILANTIN ± EFFECTS OF OTHER DRUGS ON SEIZURE THRESHOLD SUGGEST - ✓ DILANTIN LEVEL IN AM IF > 10 BUT < 20 R 200 MG PO BID. OR PREVIOUS DOSE KNOWN TO BE EFFECTIVE

SIGNATURE OF CONSULTANT

CONSULTATION REPORT

THE GETTYSBURG HOSPITAL
CRITICAL CARE UNIT
BASIC ANTI-ARRHYTHMIA THERAPY

0300410351 17-75-56

FENSON, JASON E
 KAMSLER, DAVID F MC
 E2C7A 09/27/1976 22Y M

Registered Nurses in the Critical Care Unit are authorized to act immediately in the following life threatening situations with the following medications after a reasonable diagnosis has been made and while the physician is being called

1 Death Imminent Patient unconscious

- Fixed*
30 Aug 99
0820
D - in chul
- a. Ventricular Fibrillation /Pulseless Ventricular Tachycardia
 CPR Defibrillate with 200 watt seconds * If no conversion call Code Blue, defibrillate with 300 watt seconds If no conversion, defibrillate with 360 watt seconds If still no response, give Epinephrine 1 10,000 1mg IV PUSH, defibrillate with 360 watt seconds Give Lidocaine 1mg/kg IV PUSH (not to exceed 100mg per bolus) and repeat defibrillation with 360 watt seconds Follow with Lidocaine drip of 250 D₅W with Lidocaine 1 gram at 2mg/minute Follow Code Blue Procedure
 - b. Ventricular Tachycardia (with palpable pulse)
 Defibrillate with 100 watt seconds If no response, defibrillate with 200 watt seconds If no response, call Code Blue, defibrillate with 300 watt seconds If no response, give Lidocaine 1mg/kg IV PUSH (not to exceed 100mg per bolus) and repeat defibrillation with 300 watt seconds Follow with Lidocaine drip at 250cc D₅W with Lidocaine gram 1 at 2mg/minute Follow Code Blue Procedure
 - c. Severe Bradycardia (rate less than 30)
 Atropine 1.0mg IV PUSH May repeat Atropine q. 3 - 5 minutes for total 2mg Consider CPR Prepare patient for transcutaneous pacing
 - d. Asystole
 CPR Call Code Blue Give Epinephrine 1 10,000 1mg IV PUSH CPR Give Atropine 1mg IV PUSH Follow Code Blue Procedure

2 Life Threatening. Patient still conscious but symptomatic If physician is not immediately available then

- a. Ventricular Tachycardia (3 or more PVCs in sequence)
 Lidocaine bolus 1mg/kg IV PUSH (not to exceed 100mg per bolus)
 Lidocaine drip at 2mg/minute
- b. PVCs 6 or more a minute, multi-focal in nature, coupling or occurring of T wave
 Lidocaine bolus 1mg/kg IV PUSH (not to exceed 100 mg per bolus)
 Lidocaine drip at 2mg/minute
- c. Bradycardia Rate less than 40 or 50 a minute and patient symptomatic (Consciousness altered or blood pressure dropped)
 Atropine 5mg IV PUSH If rate further drops, follow immediately with second dose of 5mg IV PUSH If rate does not significantly increase in 2 to 5 minutes, give additional 5mg IV PUSH Prepare patient for transcutaneous pacing

D - in chul

30 AUG 99 0927

Exhibit B

153
PL

IN THE UNITED STATES DISTRICT COURT
FOR THE MIDDLE DISTRICT OF PENNSYLVANIA

JARIBU IGWE MUTOPE,

Plaintiff,


v.

RANDALL EDGAR, ET AL.,

Defendants

CIVIL NO. 3:CV-98-1179

(Judge Kosik)



MEMORANDUM AND ORDER

Presently pending before the court is defendant Good Samaritan Hospital's (Moving Defendant) motion (Doc. 73) to dismiss the amended complaint for failure to state a claim pursuant to Fed. R. Civ. P. 12(b)(6). The motion has been fully briefed and is ripe for disposition. For the reasons set forth below, the motion will be granted.

Background

The above-captioned civil rights complaint pursuant to 42 U.S.C. § 1983 was filed on July 21, 1998 by Jaribu Igwe Mutope, an inmate presently confined at the State Correctional Institution, Frackville, Pennsylvania (SCI-Frackville).¹ He proceeds pro se and in forma pauperis. On March 11, 1999, plaintiff filed an amended complaint (Doc. 62).²

1. At the time Mutope filed his complaint he was confined at the Lebanon County Prison.

2. The amended complaint supersedes the original complaint. See Brandon v. Beard, 140 F.R.D. 328, 329 (M.D. Pa. 1991).

Moving Defendant filed a motion to dismiss the amended complaint (Doc. 73) together with a brief in support (Doc. 74) on June 21, 1999. Plaintiff filed briefs in opposition (Doc. Nos. 77, 78) on June 25, 1999. No reply brief has been filed.

Named as defendants are: Randall Edgar; M. Barrett; Lt. Klingler; Officers Spitler and MacNicholas; the Lebanon City Police Department; Raiger, apparently employed at the Lebanon County Correctional Facility; Dr. James Keller;³ and Good Samaritan Hospital. With respect to Moving Defendant, the amended complaint alleges that during the course of his arrest on April 29, 1997, Mutope was beaten and called racial names by certain members of the Lebanon City Police Department. As a result of this purported beating, he states that he received serious bodily injuries consisting of broken bones in multiple areas of his body, including injuries to his left and right wrists. Further, he states that he was denied medical treatment for those injuries by Dr. Keller and by various unnamed staff members at the Good Samaritan Hospital emergency room on the day of the incident as well as during his subsequent nine day stay at that facility.

In the motion to dismiss, Moving Defendant argues that it was not acting under color of state law within the meaning of § 1983 when it treated plaintiff. Further, Moving Defendant contends that, even assuming there was state action, plaintiff's allegations against it are premised solely on the theory of respondeat superior, which is not a proper basis for imposing § 1983 liability. Finally, Moving Defendant argues that, assuming

3. The name of this defendant is spelled differently in the complaint and in defendant's response, the court will use the spelling found in defendants' submissions, which is presumed to be the correct one.

plaintiff had sufficiently alleged that it acted under color of state law, he has failed to state a claim because he fails to allege any deliberate indifference to his serious medical needs. Conversely, plaintiff argues that Good Samaritan was acting under color of state law because when he was brought to that facility on April 29, 1997 he was in the custody of the Lebanon City Police and in handcuffs. He remained in handcuffs for hours despite complaints to hospital medical personnel that his injuries were being affected by the handcuffs. He also states that he was only released from police custody when they realized how serious his injuries were and, was subsequently discharged by his doctor via the telephone to the police on May 7, 1997. Further, plaintiff argues that by refusing to respond to his complaints of pain due to the handcuffs and the injuries to his hands, the hospital was deliberately indifferent to his serious medical needs.

Based upon a careful review of the pleadings and briefs, the court is of the view that Moving Defendant's motion to dismiss for failure to state a claim can be granted as the complaint against it suffers from a fatal deficiency which can not be cured by amendment.

Discussion

A court, in rendering a decision on a motion to dismiss, must accept the veracity of the plaintiff's allegations. White v. Napoleon, 897 F.2d 103, 106 (3d Cir. 1990). In Nami v. Fauver, 82 F.3d 63, 65 (3d Cir. 1996), the Court of Appeals for the Third Circuit added that when considering a motion to dismiss based on a failure to state a claim argument, a court should "not inquire whether the plaintiffs will ultimately prevail, only whether they are entitled to offer evidence to support their claims." "[A] complaint should not be dismissed for failure to state a claim unless it appears beyond doubt that the plaintiff can prove no set

of facts in support of his claim which would entitle him to relief." Conley v. Gibson, 355 U.S. 41, 45-46 (1957).

"The test in reviewing a motion to dismiss for failure to state a claim is whether, under any reasonable reading of the pleadings, plaintiff may be entitled to relief." Holder v. City of Allentown, 987 F.2d 188, 194 (3d Cir. 1993) (citation omitted). Additionally, a court must "accept as true the factual allegations in the complaint and all reasonable inferences that can be drawn from them." Markowitz v. Northeast Land Co., 906 F.2d 100, 103 (3d Cir. 1990); Independent Enters., Inc. v. Pittsburgh Water & Sewer Auth., 103 F.3d 1165, 1168 (3d Cir. 1997). Finally, it is additionally well-settled that pro se complaints should be liberally construed. Haines v. Kerner, 404 U.S. 519, 520 (1972).

In order to assert an actionable civil rights claim, plaintiff must allege that some person has deprived him of a federal right, and that the person who caused the deprivation acted under color of state law. West v. Atkins, 487 U.S. 42, 48 (1988); Gorman v. Township of Manalapan, 47 F.3d 628, 638 (3d Cir. 1995); Barna v. City of Perth Amboy, 42 F.3d 809, 815 (3d Cir. 1994). Since one of the essential elements of a § 1983 action is the requirement that the person acted under color of state law, "... state action is a threshold issue in any section 1983 case." Bonenberger v. Plymouth Township, 132 F.3d 20, 23 (3d Cir. 1997); Gorman, 47 F.3d at 638. Action under color of state law requires "that the defendant in a § 1983 action have exercised power 'possessed by virtue of state law and made possible only because the wrongdoer is clothed with the authority of state law.'" West, 487 U.S. at 49. "A private action is not converted into one under color of state law merely by some tenuous connection to state action. The issue is not whether the state was

involved in some way in the relevant events, but whether the action taken can be fairly attributed to the state itself." Gorman, 47 F.3d at 638. Without state action there can be no § 1983 liability. Gorman, Id. The burden of proof on the issue of action under color of state law rests with the plaintiff. West, 487 U.S. at 48; Gorman, Id.

There are three test for detecting the presence of action under color of state law: (1) "traditional exclusive governmental function," test, which extends to "... only those activities that have been 'traditionally the exclusive prerogative of the State'"; (2) the symbiotic relationship test, which"... examines the relationship between the state and the alleged wrongdoer to discern whether there is a great degree of interdependence between the two;" and (3) the "close nexus test, ... [wherein] the inquiry is 'whether there is a sufficiently close nexus between the State and the challenged action of the regulated entity so that the action of the latter may be fairly treated as that of he State itself.'" Klavan v. Crozer-Chester Medical Center, 60 F. Supp.2d 436, 441-42 (E.D. Pa. 1999); Gorman, 47 F.3d at 639-40. The court is of the view that plaintiff's allegations as to Good Samaritan Hospital fail to establish that that defendant acted under color of state law in its treatment of him under any of these tests.

The only allegations against the Moving Defendant stem from its treatment of plaintiff at the emergency room on the date of his initial arrest and for the nine days thereafter he contends he was hospitalized. Courts have held that the provision of hospital services is not a traditional public function exclusively reserved to the state. Klavan, 60 F. Supp.2d at 441, n.5. Therefore, something more is required before Good Samaritan's conduct in this case can be said to constitute state action. However, the fact that plaintiff

was initially brought to the hospital by the police, kept in handcuffs for a time, and ultimately discharged to the police, does not transform otherwise private action into state action. Instructive on this point is the decision reached in Mcllwain v. Prince William Hospital, 774 F. Supp. 986 (E.D. Va. 1991). In Mcllwain, a former prison inmate filed a § 1983 civil rights complaint against the prison and the hospital, where he was brought for emergency care after lapsing into unconsciousness from a heroin overdose, for failure to inform him that during his two day hospital stay his blood had been tested for HIV and had come back positive. He was not informed of the positive test results by prison doctors either and after his release contended that he transmitted the virus to his wife. In finding that the hospital was not a state actor within the meaning of § 1983, the court stated:

... no contractual relationship existed between the Hospital and the Haymarket Correctional Facility. The prison did not routinely treat inmates at the Hospital. Rather, Mcllwain was rushed to the Hospital because he needed emergency care. A hospital's mere acceptance of a prison inmate for emergency care does not transform the hospital into a state actor. By seeking emergency treatment for Mcllwain, the prison did not delegate its duty to provide him with medical care; the Hospital admitting Mcllwain to its emergency room, did not accept any such duty. The Hospital was not 'fully vested with state authority ... to provide essential medical care to those the State had incarcerated.' West v. Atkins, 108 S.Ct. at 2260. In short, the Hospital was not a state actor.


Mcllwain, 774 F. Supp. at 989-90. It also follows that, for the same reasons, the factual allegations against Good Samaritan fail to demonstrate a close nexus between that defendant and the conduct of the police, so as to render the conduct of the former state action.

Moreover, as Moving Defendant correctly contends, if there was state action by

Good Samaritan, it cannot be held liable to plaintiff on the basis of respondeat superior. Claims brought under § 1983 cannot be premised on a theory of respondeat superior. Rode v. Dellarciprete, 845 F.2d 1195, 1207 (3d Cir. 1988). Moving Defendant cannot be held vicariously liable for the conduct of its employees unless plaintiff alleges a policy, which he does not. McIlwain, 774 F. Supp. at 990; Temple v. Albert, 719 F. Supp. 265, 268 (S.D.N.Y. 1989) (finding private hospital not vicariously liable under § 1983 for acts of its employees).

Consequently, the motion to dismiss filed by Good Samaritan will be granted and that defendant will be dismissed from this action. An appropriate order follows.

ACCORDINGLY, THIS ¹⁴20 DAY OF MARCH, 2000, IT IS HEREBY ORDERED THAT: the motion to dismiss (Doc. 73) filed on behalf of defendant Good Samaritan Hospital is GRANTED and that defendant is dismissed from this action.


EDWIN M. KOSIK
United States District Judge

EMK:mcs

CERTIFICATE OF SERVICE

I, John R. Kantner, Esquire, an employee of the law firm of Post & Schell, P.C., do hereby certify that on the date set forth below, I did serve a true and correct copy of foregoing document upon the following person at the following address indicated below by sending same in the United States mail, first-class, postage prepaid:

Jason Eric Benson
SCI-SM
DS-6483
PO Box 999
1120 Pike Street
Huntingdon, PA 16652

Thomas Duran, Warden
Adams County Prison
Gettysburg, PA 17325

Bruce Cluck, Deputy Warden
417 West Middle Street
Gettysburg, PA 17325

Debra Hankey, Deputy Warden
Adams County Prison
Gettysburg, PA 17325

Lt. John Jennings
73 Fourth Street
PO Box 155
Biglerville, PA 17307

Lt. William Orth
236 West Main Street
Waynesboro, PA 17268

Sgt. Rae Hientzelman
Adams County Prison
Gettysburg, PA 17325

C.O. Briton Shelton
Adams County Prison
Gettysburg, PA 17325

C.O. David Vazquez
670 Quaker Run Road
Aspers, PA 17304

C.O. Jane Doe
Adams County Prison
Gettysburg, PA 17325


C.O. John Doe
Adams County Prison
Gettysburg, PA 17325

Adams County Prison
Adams County Prison
Gettysburg, PA 17325

James D. Young, Esquire
Lavery, Flaherty, Young & Patterson, P.C.
P.O. Box 1245
Harrisburg, PA 17108-1245

Date:

10/10/00



John R. Kantner, Esquire